Cardiovascular involvement in systemic autoimmune diseases

Abstract

Autoimmune diseases, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), primary antiphospholipid syndrome (APS), systemic sclerosis and systemic vasculitis, affect a large number of people in whom one of the leading causes of morbidity and mortality is cardiovascular disease. Cardiovascular disease is associated with the development of accelerated atherosclerosis. It seems to occur at a younger age than in the general population, is often asymptomatic and, in addition to traditional risk factors, also involves specific risk factors as chronic inflammation, the duration and activity of the autoimmune disease, and immunosuppressive therapy. The early phases of cardiovascular involvement in patients with autoimmune diseases may be clinically silent, with only a microcirculation disorder present. There are various means of detecting morphological cardiac damage: coronary angiography remains the gold standard for diagnosing coronary stenosis, but new, non invasive and more reliable methods have been introduced into clinical practice in order to detect subclinical microcirculation abnormalities.

Introduction

Systemic autoimmune diseases make up a family of conditions that share common pathogenetic mechanisms and multi-organ involvement including the heart. Autoimmune diseases occur because the physiological tolerance to self-antigens is lost and, although circulating antibodies do not always play a pathogenetic role, they represent specific markers of ongoing tissue damage. In the case of systemic autoimmune diseases, the autoantibodies are against ubiquitous antigens (i.e. nuclear antigens in systemic lupus erythematosus or SLE), and the tissue damage is generalised.

Systemic autoimmune diseases affect many patients with rheumatoid arthritis (RA), SLE, primary antiphospholipid syndrome (APS), systemic sclerosis and systemic vasculitis, in whom one of the leading causes of morbidity and mortality is cardiovascular disease, which is associated with the development of accelerated atherosclerosis [1], [2]: for example, cardiovascular mortality accounts for 40–50% of all deaths in RA [3]. Furthermore, cardiovascular disease seems to occur at a younger age than in the general population, is often asymptomatic (at least in the early stages) and, in addition to traditional risk factors, also involves specific risk factors. In particular, the excess cardiovascular mortality and morbidity can be explained by chronic inflammation, the duration and activity of the autoimmune disease, and the effects of immunosuppressive therapy (glucocorticoids and methotrexate) [4]. Wolfe et al. [5] have observed that minimal disease activity and a short disease duration are associated with better outcomes in RA.

All of the components of the heart can be affected by a number of pathogenetic mechanisms that may involve the valves, the coronary arteries, the conduction system, or the myocardium, endocardium or pericardium. The clinical manifestations of cardiac involvement include: pericarditis, myocarditis and myocardial fibrosis, rhythm and conduction disturbances, coronaritis with ischemic heart disease, valvular diseases, pulmonary hypertension, syncope, and diastolic or systolic heart failure [1], [6].

It has recently been recognised that chronic inflammation plays an important role in the development of atherosclerotic plaque [7], [8], [9], and the prime mover in this process seems to be endothelial dysfunction [10], which is largely characterised by a reduction in nitric oxide (NO) production by NO synthase. Asymmetric dimethyl arginine (ADMA) is an endogenous inhibitor of NO synthase and has recently emerged as a novel marker of cardiovascular risk; it has already been demonstrated that plasma ADMA levels are high in RA patients [11]. Moreover, it has been shown that anti-rheumatic drugs reduce systemic inflammation and may improve endothelial dysfunction [12], and the same effect has been observed after statin therapy [13], [14].

As autoimmune diseases are characterised by a high degree of cardiovascular risk, and cardiac involvement is associated with adverse outcomes and a poor prognosis, the early identification of patients at higher risk is essential. Knowing the mechanisms responsible for cardiovascular damage in systemic autoimmune diseases is an important step in choosing appropriate drugs that can block/slow the development of atherosclerosis.